A Regulatory Solution in Search of a Problem
FDA’s implementation of a presidential terminology mandate raises questions about scientific accuracy, regulatory consistency, and the responsible use of limited public health resources.
Beginning November 16, 2026, the U.S. Food and Drug Administration (FDA) will replace the terms Artificial Intelligence (AI) with Super Intelligence (SI) in newly issued public-facing communications and documents, pursuant to Executive Order 14434, signed by President Donald Trump on September 29, 2026.
The change is already visible across FDA’s website, where visitors are greeted with an announcement announcing the transition to the new terminology.
The administration maintains that the new designation better reflects the extraordinary capabilities and potential of emerging technologies. However, from a scientific and regulatory perspective, the mandate raises a fundamental question: What problem does this terminology change solve?
For an agency responsible for protecting public health, operating with limited resources, and confronting increasingly complex regulatory challenges, the answer is far from apparent.
Artificial Intelligence and Superintelligence Are Not the Same Thing
Artificial intelligence is a broad scientific and technological discipline encompassing systems designed to perform tasks that ordinarily require aspects of human intelligence. These include machine learning, pattern recognition, natural language processing, predictive analytics, computer vision, and automated decision-making. Artificial superintelligence, by contrast, generally refers to a hypothetical form of intelligence that substantially exceeds human cognitive capabilities across a broad range of domains.
The distinction is significant. A medical device that uses machine learning to identify suspicious pulmonary nodules is not superintelligent. Neither is an algorithm designed to detect diabetic retinopathy, predict cardiac arrhythmias, or identify potential medication interactions.
These technologies may outperform humans in narrowly defined tasks, but that does not make them superintelligent systems. Even today’s sophisticated generative AI systems have significant limitations involving accuracy, reliability, reasoning, and contextual understanding.
Ironically, Executive Order 14434 initially defines Super Intelligence using the existing statutory definition of artificial intelligence under 15 U.S.C. § 9401(3). In other words, the terminology has changed, but the underlying legal definition has not. The mandate does not establish that existing AI technologies have achieved superintelligence. It simply directs federal agencies to call them something different.
The Administrative Burden of Renaming a Technology
For FDA, implementing this mandate involves considerably more than changing a banner on its website. Artificial intelligence terminology is embedded throughout the agency’s regulatory infrastructure, including guidance documents, scientific publications, regulatory policies, submission templates, databases, educational materials, and communications with regulated industries.
FDA has indicated that existing documents will remain effective as written and that terminology changes will generally be incorporated during scheduled substantive revisions and routine maintenance activities.
Nevertheless, implementing the transition will involve work across multiple areas, including the review, revision, and republishing of affected guidance documents as they undergo substantive revision. Then there will be changes to digital communication such as websites, databases, search functions, and electronic submission systems are updated.
On the administrative side, FDA will need to revise agency forms, templates, educational resources, and training materials. And reconcile the terminology change across FDA centers, offices, and regulatory programs. All while maintaining consistency with existing statutory and regulatory language.
And following those updates, FDA will need to communicate the changes to manufacturers, healthcare professionals, researchers, and international regulatory authorities who still use the term artificial intelligence. A global search-and-replace operation cannot adequately address these issues. Scientific terminology, legal references, recognized consensus standards, document titles, and historical regulatory records require careful consideration.
FDA must also preserve the ability of stakeholders to locate and understand existing information using the terminology that has been established throughout decades of scientific research and regulatory practice. The agency’s decision to incorporate these changes into normal maintenance cycles is a reasonable effort to minimize disruption but will cause a growing mismatch of terms between legacy documentation and the changed versions. And it does not, however, eliminate the additional administrative burden.
What About Existing Regulations?
The executive order does not currently require FDA to amend previously issued regulations, and FDA has confirmed that existing regulations and guidance documents remain effective as written.
However, the executive order also directs the Assistant to the President for Science and Technology to develop proposed legislative language establishing a federal definition of Super Intelligence and identifying potential amendments to existing statutory references to artificial intelligence.
Should these proposals ultimately result in statutory changes, additional regulatory revisions could become necessary. Depending on their nature, such revisions could involve legal review, rulemaking, Federal Register publication, public comment, and corresponding updates to regulatory guidance and implementation materials.
What begins as a terminology change could therefore evolve into a considerably more extensive regulatory undertaking, all at the taxpayers’ expense.
An Agency Already Facing Resource Constraints
The timing of this mandate is particularly concerning. In February 2026, the U.S. Government Accountability Office (GAO) reported that FDA continues to face challenges recruiting, retaining, and training personnel. These challenges have affected the agency’s ability to conduct inspections and fulfill important oversight responsibilities.
FDA has also experienced substantial workforce reductions, followed by efforts to rebuild its scientific and regulatory staffing capacity. Meanwhile, the administration’s FY 2027 budget request proposes approximately $3.306 billion in FDA appropriated budget authority, compared with $3.354 billion enacted for FY 2026 – a proposed reduction of approximately $47.8 million, separate from industry user fee funding.
These resource constraints come at a time when FDA must address numerous public health and regulatory priorities. The agency must also continue developing meaningful regulatory frameworks for artificial intelligence itself, addressing issues such as algorithmic bias, clinical performance, cybersecurity, data integrity, transparency, and lifecycle management.
These are substantive scientific and regulatory challenges that directly affect patient safety. And renaming the technology does not resolve any of them.
The Cost of the Mandate
There is no publicly identified comprehensive estimate of what implementing the terminology change will cost FDA. However, the absence of a dedicated budget allocation does not mean that implementation is without cost.
Staff time devoted to reviewing terminology, revising documents, updating information systems, coordinating implementation, and addressing stakeholder questions represents resources that could otherwise support the agency’s public health mission. Even when incorporated into scheduled maintenance activities, these additional tasks consume personnel time and organizational capacity.
For an agency funded through both congressional appropriations and industry user fees, responsible resource allocation is not simply an administrative preference. It is an obligation to taxpayers, regulated industries, and the patients who depend on effective regulatory oversight.
Implications for International Regulatory Harmonization
The medical device and pharmaceutical industries operate within an increasingly interconnected global regulatory environment.
FDA has worked extensively with international regulatory authorities, including Health Canada, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, and members of the International Medical Device Regulators Forum, to establish common approaches to artificial intelligence and machine learning-enabled medical technologies.
International standards organizations, scientific researchers, regulatory authorities, and manufacturers have developed an extensive body of technical terminology to support these efforts. The unilateral adoption of Super Intelligence as a replacement for artificial intelligence introduces an unnecessary inconsistency into that environment.
Manufacturers may now encounter different terminology in FDA communications, international standards, European regulatory requirements, scientific publications, and their own technical documentation, even when these materials describe identical technologies.
FDA has appropriately clarified that manufacturers, sponsors, and applicants are not required to adopt the new terminology. Nevertheless, the change creates another layer of terminology reconciliation for organizations already navigating complex international regulatory requirements.
Scientific Precision Should Remain a Regulatory Priority
We support the responsible development and application of artificial intelligence in medical devices, pharmaceutical development, manufacturing, regulatory science, and healthcare. These technologies offer extraordinary opportunities to improve patient outcomes, accelerate innovation, and enhance regulatory effectiveness.
But realizing those opportunities requires scientific precision, evidence-based decision-making, and a clear understanding of technological capabilities and limitations. Characterizing all artificial intelligence technologies as super intelligence risks obscuring those distinctions rather than improving them.
The concern is not whether FDA should embrace emerging technologies. It should. The concern is whether a politically directed change in scientific terminology represents a meaningful contribution to that objective.
A Question of Priorities
FDA’s responsibility is to protect and promote public health. Its effectiveness depends on the expertise of its personnel, the quality of its scientific assessments, the integrity of its regulatory decisions, and the efficient use of its resources.
At a time when the agency is rebuilding its workforce and confronting significant regulatory challenges, the administration should be able to demonstrate a tangible public benefit before directing resources toward an extensive terminology transition.
What measurable improvement in patient safety, regulatory efficiency, scientific understanding, or technological innovation will result from replacing artificial intelligence with Super Intelligence? Until that question can be answered, the mandate appears to represent an administrative solution to a problem that has not been demonstrated to exist.
Artificial intelligence does not become more intelligent because the government changes its name. And FDA does not become a more effective regulatory agency by being required to do so.
Where Was the Stakeholder Consultation?
A departure from established regulatory practices
One of the distinguishing characteristics of FDA’s regulatory framework is its commitment to transparency, scientific evaluation, and stakeholder participation.
Under the Administrative Procedure Act (5 U.S.C. § 553), substantive regulatory changes generally require public notice and an opportunity for comment. FDA’s Good Guidance Practices (21 CFR § 10.115) similarly establish procedures for stakeholder participation in the development of significant regulatory guidance.
These processes serve an important purpose. They allow scientists, healthcare professionals, manufacturers, professional associations, and other stakeholders to evaluate proposed changes, identify unintended consequences, and contribute to informed regulatory decision-making.
The presidential mandate replacing Artificial Intelligence with Super Intelligence does not appear to have undergone a comparable public consultation process. Although the executive order was published in the Federal Register, publication of an executive order is not equivalent to notice-and-comment rulemaking.
Because the immediate initiative concerns agency terminology rather than substantive regulatory requirements, formal notice-and-comment procedures may not be legally required. However, the absence of a legal requirement does not diminish the potential value of stakeholder consultation.
Several questions remain unanswered
- What scientific evidence supports the terminology change?
- Were scientific and engineering professional organizations consulted?
- Were international regulatory partners given an opportunity to evaluate the implications?
- Was an economic or regulatory impact assessment conducted?
- What measurable public benefit is expected?
Perhaps more concerning, Section 3(b) of the executive order directs the development of proposed legislative language that could modify or supersede the existing statutory definition of artificial intelligence. The initiative could therefore extend well beyond an administrative terminology change.
There is a considerable irony in this approach. FDA routinely expects regulated manufacturers to justify proposed changes, assess their potential risks, evaluate unintended consequences, and document the rationale for their decisions. These expectations reflect sound scientific, engineering, and quality management principles.
Should the federal government not apply comparable principles when directing changes to the scientific and regulatory infrastructure itself? The issue is not simply whether the administration has the authority to mandate a terminology change. It is whether the process reflects the standards of transparency, scientific rigor, and evidence-based decision-making that FDA expects of the industries it regulates.
When Apparel Becomes a Medical Device
Lessons from FDA’s Breast Binder Warning Letters In December 2025, the FDA issued warning letters to several companies selling breast binders and chest compression garments online. The agency concluded that marketing claims on company websites, like statements about...
Ethicon Issues Safety Alert for Surgical Stapler Cartridge
Endopath Echelon Vascular White Reload for Advanced Placement TipSource: FDAUrgent Class I Medical Device Recall Ethicon Endo-Surgery, LLC has issued an urgent correction for its Endopath Echelon Vascular White Reload for Advanced Placement Tip (35 mm, 4-row). This...
FDA Cracks Down on Insightra Medical
Warning Letter Cites a Number of Serious Violations In a scathing warning letter, the FDA has cited Insightra Medical, Inc. for widespread regulatory violations involving its Intra-Aortic Balloon Pump (IABP) Catheter Kit—a device used in critical cardiovascular...
FDA Cracks Down on Illegally Marketed 7-OH Products
Unapproved drugs sold online and in retail locations Yesterday the U.S. Food and Drug Administration (FDA) issued seven warning letters to companies marketing products that contain 7-hydroxymitragynine (7-OH) — a powerful and potentially dangerous opioid-like...
Sterile Drug Manufacturing Violations at Daewoo Pharmaceutical
FDA Cracks Down on Sterile Drug Manufacturing Violations The U.S. Food and Drug Administration (FDA) has issued a warning letter to Daewoo Pharmaceutical Co., Ltd. in Busan, South Korea, citing serious and widespread violations of current Good Manufacturing Practices...
Mechanical Circulatory Support (MCS) Devices
Overview of MCS Devices Mechanical Circulatory Support (MCS) devices have transformed the landscape of advanced heart failure treatment. From temporary stabilization in cardiogenic shock to long-term support as destination therapy, these technologies bridge critical...
Recall Alert: AirLife/Vyaire Infant Breathing Systems
Class I Recall AirLife and manufacturer Vyaire are recalling specific Infant Heated Wire Circuits due to the risk that accessory adapters may disconnect during use, especially once the system reaches operating temperature. This could lead to serious injury or death,...
Avanos Recalls Ballard Closed Suction Systems
May result in non-sterile devices Avanos Medical, Inc. is recalling its Ballard Closed Suction Systems after identifying a failure in the sterilization process, which may result in non-sterile devices. Use of these products could lead to serious health risks,...
FDA Alert: Abiomed Impella Blood Pump Controller
Abiomed Impella blood pump controllers Controller May Fail to Detect Device Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when...
GE HealthCare Anesthesia Systems Recall Due to Ventilation Risk
GE Carestation Anesthesia Systems GE HealthCare has issued a high-priority correction for certain Carestation anesthesia systems due to a potentially life-threatening risk when used in Volume Control Ventilation (VCV) mode. Affected Devices Carestation 620, 650, 650c...


